VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | The long-term safety and efficacy of ibrutinib monotherapy in patients with previously-treated WM

Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the long-term safety and efficacy of ibrutinib monotherapy in patients with previously treated Waldenström’s macroglobulinemia (WM), including those with MYD88 and CXCR4 mutations. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter